Kymera Revenue Drops 55 Percent in Q2

Kymera Therapeutics (NASDAQ:KYMR), a biotechnology company recognized for its targeted protein degradation technology, released its second quarter 2025 results on August 11, 2025. The most notable news was a sharp decline in GAAP revenue for Q2 2025, with reported revenue of $11.48 million versus analysts' estimates of $22.24 million—a 48.4% shortfall, coupled with increased operating losses driven by higher research spending. GAAP revenue was $11.5 million, well below the estimated $22.24 million (GAAP). GAAP loss per share (EPS) was $(0.95), also worse than the anticipated $(0.81) GAAP EPS. Research expense surged due to increased investment in the STAT6 program, platform and discovery programs, and growth in the research and development organization. The quarter highlighted significant scientific progress, but GAAP financial performance trailed expectations. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Kymera specializes in targeted protein degradation (TPD), a novel drug discovery approach that uses small molecules to direct the body’s cellular machinery to eliminate proteins involved in disease. This enables the company to address conditions that have been resistant to older drug technologies. The company's current strategy centers on applying TPD to immunology, aiming to treat diseases like atopic dermatitis, asthma, lupus, and rheumatoid arthritis with degraders that offer the benefits of biologic drugs in convenient oral form.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool